Medical Condition News

RSS

Hospitals striving to provide balloon angioplasties in under 60 minutes for patients undergoing heart attacks

National guidelines say patients undergoing heart attacks should receive balloon angioplasties as soon as possible or within 90 minutes of arriving at the hospital -- known as the "door-to-balloon time."

23 Apr 2010

Scientists develop new way of modifying viruses to seek out and destroy cancer cells

CANCER RESEARCH UK scientists at the University of Leeds have developed a new way of modifying viruses to seek out and destroy cancer cells, according to research published in Gene Therapy today1 (Friday).

23 Apr 2010

Potential new early cancer detection method using engineered gold nanoparticles

University of Missouri School of Medicine scientists explain a potentially new early cancer detection and treatment method using nanoparticles created at MU in an article published in the Proceedings of the National Academy of Sciences. The article illustrates how engineered gold nanoparticles tied to a cancer-specific receptor could be targeted to tumor cells to treat prostate, breast or lung cancers in humans.

23 Apr 2010

Study describes relationship between gene expression and intelligence in WS patients

Although genetics is the most significant known determinant of human intelligence, how specific genes affect intelligence remains largely unknown. A multi-institution team led by a University of Utah USTAR researcher has found that the brain gene STX1A plays a significant role in the level of intelligence displayed by patients with Williams Syndrome.

23 Apr 2010

CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia

Central Admixture Pharmacy Services, Inc. (CAPS®), a B. Braun company, announced today the launch of its newest service for the admixture and delivery of Hibernation Therapeutics' patented Adenocaine™ microplegia, the world's first low-potassium, non-depolarizing cardioplegia solution.

From B. Braun Melsungen AG 23 Apr 2010

Treating OSA in truck drivers lowers healthcare costs and disability rates: Study

For commercial motor vehicle drivers with obstructive sleep apnea, effective treatment lowers healthcare costs and disability rates, reports a study in the May Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine.

23 Apr 2010

Hospital for Special Care launches ALS Clinical Trials Unit at Neuromuscular Center

Hospital for Special Care announced today the launch of the region's first Amyotrophic Lateral Sclerosis (ALS) Clinical Trials Unit at its Neuromuscular Center. The new unit will be headed by Jinsy A. Andrews, M.D., a physician researcher recruited from Columbia University. Dr. Andrews, Director of Research & Clinical Trials Unit, Hospital for Special Care, specializes in neuromuscular research and will facilitate the hospital's first clinical trial for ALS upon her arrival.

23 Apr 2010

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

Genentech, Inc., a wholly owned member of the Roche Group, announced today that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Herceptin® (trastuzumab) plus chemotherapy in people with advanced, HER2-positive adenocarcinoma of the stomach, including gastroesophageal junction cancer.

23 Apr 2010

Mayo Clinic study finds changes in tissue damage throughout the course of MS

A new Mayo Clinic study has found that the type of tissue damage changes throughout the course of multiple sclerosis. In early relapsing disease stages, the plaques, or areas where the nervous system is inflamed or demyelinated, are predominantly active with distinct heterogeneous patterns of myelin damage.

23 Apr 2010

COSMOS project launched to investigate link between use of mobile phones and health problems

A new decades-long study launches today to investigate whether there is a link between the use of mobile phones and long-term health problems such as cancer.

23 Apr 2010

Affymax institutes quiet period in connection with Hematide Phase 3 result analysis

Affymax, Inc. today announced that it has instituted a quiet period to curtail discussions with the investor community and the media in connection with the analysis of Phase 3 results for the investigational drug, Hematide, in four clinical trials (PEARL 1, PEARL 2, EMERALD 1 and EMERALD 2) which evaluated Hematide for the treatment of anemia in chronic renal failure patients.

23 Apr 2010

BSD-2000 Hyperthermia System combined with chemotherapy promising for children with high-risk tumors

BSD Medical Corporation today reported clinical study data showing that hyperthermia, using the BSD-2000 Hyperthermia System, combined with chemotherapy has the potential to improve control rate and long-term survival for the treatment of children with high-risk cancer who have a dismal prognosis.

23 Apr 2010

SVS publishes first supplement on diversity articles to Journal of Vascular Surgery

The Society for Vascular Surgery published its first supplement on diversity articles to its Journal of Vascular Surgery in April 2010.

23 Apr 2010

Tryton Medical widens European availability of Side Branch Stent System

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced the launch of the TRYTON Side Branch Stent™ System in Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom. The stent is used to treat bifurcation lesions, the largest unmet need confronting interventional cardiology.

23 Apr 2010

Gelesis presents Attiva data at AACE 19th Annual Meeting & Clinical Congress

Boston-based medical technology firm Gelesis, Inc. unveiled its capsulated device Attiva™, and presented data showing that Attiva™ significantly increased the post-meal feeling of satiety and reduced hunger between meals in obese patients. This data was presented today at the American Association of Clinical Endocrinologists (AACE) 19th Annual Meeting & Clinical Congress.

23 Apr 2010

Biological activity of Curis' CUDC-101 HDAC, EGFR and HER2 inhibitor published in Cancer Research

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a research paper describing the biological activity of its HDAC, EGFR and HER2 inhibitor, CUDC-101, was published online in the journal Cancer Research and also will be published in an upcoming print version of the journal.

23 Apr 2010

Data from pivotal study of Marqibo in ALL patients to be presented at ASCO meeting

Hana Biosciences, a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that complete data from its pivotal study of Marqibo in patients with relapsed/refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia, have been accepted for an oral podium presentation at the 46th Annual Meeting of the American Society of Clinical Oncology to be held June 4-8, 2010 in Chicago, Illinois.

23 Apr 2010

FDA Advisory Committees vote against approval of Acurox NDA

Acura Pharmaceuticals, Inc. and King Pharmaceuticals®, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Anesthetic and Life Support Drugs and Drug Safety and Risk Management Committees voted that they do not have enough evidence to support the approval of the New Drug Application (NDA) for Acurox® (oxycodone HCl and niacin) Tablets for the treatment of moderate to severe pain, considering the deterrent effects of niacin as well as the potential deterrent effects of the other features specific to Acurox®.

23 Apr 2010

Physical exercise and computer use may help protect against mild cognitive impairment: Mayo Clinic

A new Mayo Clinic study found that physical exercise and computer use may help protect against mild cognitive impairment, a disorder of the brain that affects nerve cells involved in thinking abilities.

23 Apr 2010

Celator Pharmaceuticals presents data on CPX-351 Liposome Injection and HDPN formulation

Celator Pharmaceuticals today announced data from animal studies demonstrating the superior bone marrow uptake of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, its lead clinical-stage program, as well as the enhanced circulation kinetics and efficacy of its preclinical hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation were presented at the 101st Annual Meeting of the American Association for Cancer Research in Washington, DC (Abstracts 3698 and 5534).

23 Apr 2010

Medical Condition News

Hospitals striving to provide balloon angioplasties in under 60 minutes for patients undergoing heart attacks

Scientists develop new way of modifying viruses to seek out and destroy cancer cells

Potential new early cancer detection method using engineered gold nanoparticles

Study describes relationship between gene expression and intelligence in WS patients

CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia

Treating OSA in truck drivers lowers healthcare costs and disability rates: Study

Hospital for Special Care launches ALS Clinical Trials Unit at Neuromuscular Center

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

Mayo Clinic study finds changes in tissue damage throughout the course of MS

COSMOS project launched to investigate link between use of mobile phones and health problems

Affymax institutes quiet period in connection with Hematide Phase 3 result analysis

BSD-2000 Hyperthermia System combined with chemotherapy promising for children with high-risk tumors

SVS publishes first supplement on diversity articles to Journal of Vascular Surgery

Tryton Medical widens European availability of Side Branch Stent System

Gelesis presents Attiva data at AACE 19th Annual Meeting & Clinical Congress

Biological activity of Curis' CUDC-101 HDAC, EGFR and HER2 inhibitor published in Cancer Research

Data from pivotal study of Marqibo in ALL patients to be presented at ASCO meeting

FDA Advisory Committees vote against approval of Acurox NDA

Physical exercise and computer use may help protect against mild cognitive impairment: Mayo Clinic

Celator Pharmaceuticals presents data on CPX-351 Liposome Injection and HDPN formulation

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Latest News